AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 246.49B +26.1% |
| Revenue (ttm) | 52.42B +9.9% |
| Net Income | 9.01B +33.7% |
| EPS | 5.76 +33.6% |
| Shares Out | n/a |
| PE Ratio | 27.36 |
| Forward PE | 17.57 |
| Dividend | 2.71 (1.69%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | n/a |
| Average Volume | 824 |
| Open | 160.70 |
| Previous Close | 160.70 |
| Day's Range | 160.70 - 160.70 |
| 52-Week Range | 115.40 - 180.45 |
| Beta | n/a |
| RSI | 41.17 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial
AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, showed significantly improved survival rate in patients with muscle-invasive bla...
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with A...
AstraZeneca (AZN) Reflects on Changes in FDA Leadership
AstraZeneca (AZN) Reflects on Changes in FDA Leadership
AstraZeneca (AZN) Reports Positive CALYPSO Phase III Trial Results
AstraZeneca (AZN) Reports Positive CALYPSO Phase III Trial Results
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory ...
AstraZeneca says CALYPSO Phase III trial met composite primary endpoint
AstraZeneca (AZN) said positive results from the CALYPSO Phase III trial showed that eneboparatide, an investigational parathyroid hormone 1 receptor agonist, met its composite primary endpoint, demon...
AstraZeneca's Ongoing Vaccine Debate Amid Health Secretary's Quest for Evidence
AstraZeneca's Ongoing Vaccine Debate Amid Health Secretary's Quest for Evidence
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
How AstraZeneca Plans to Hit $80 Billion in Revenue and Expand in the U.S.
IRW-News: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2 …
IRW-PRESS: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2026 Planung im Tempo des Wandels
CDT Equity announces AZD5904 progresses into patent cooperation treaty phase
CDT Equity (CDT) announced that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca (AZN), has progressed into the patent cooperation treaty phase. A total of 18...
Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions
Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions
What does AstraZeneca's £300m investment mean for Cambridge?
Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.
AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)
AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for AstraZeneca Plc (NASDAQ:AZN), endorsing its prostate cancer regimen while declinin...
AstraZeneca stock falls after FDA panel votes against new cancer drug
An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. Astr...
ODAC recommends AstraZeneca Truqap for hormone-sensitive prostate cancer
The FDA Oncologic Drugs Advisory Committee, or ODAC, has recognized a favorable benefit risk profile for AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen deprivation therapy, or...
AstraZeneca: FDA Panel Recommends Truqap Combination For PTEN-Deficient Prostate Cancer
(RTTNews) - AstraZeneca (AZN) announced that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of Truqap in combination with abiraterone and androgen deprivation therap...
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer candidate after the drug failed to get backing at a key advisory committee vote.
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug
Shares of AstraZeneca fell 1.7% on Friday after an advisory panel for the U.S. Food and Drug Administration overnight voted against recommending the British drugmaker's experimental breas...
AstraZeneca: Advisory Committee Recognises Favourable Benefit Risk Profile For Truqap Combination
LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the FDA's Oncologic Drugs Advisory Committee or ODAC has recognised a favourable benefit risk profile for AstraZeneca's Truqap in c...
TRUQAP (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP (capivasertib) in combination with abirat...
AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment
AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment
AstraZeneca says FDA AdCom recommend Truqap in mHSPC
The company states: “The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognised a favorable benefit risk profile for AstraZeneca’s (AZN) Truqap (capivasertib) in combinati...
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant